Clinical Trial Simulations for Dosage Optimization of Docetaxel in Patients with Liver Dysfunction, Based on a Log-binominal Regression for Febrile Neutropenia

This study was aimed to perform clinical trial simulations to evaluate the dose reduction strategy of docetaxel for Japanese patients with liver dysfunction, which we previously proposed. For this purpose, a log-binominal regression (LBR) was performed for febrile neutropenia (FN) induced by docetax...

Full description

Saved in:
Bibliographic Details
Published inYAKUGAKU ZASSHI (Journal of the Pharmaceutical Society of Japan) Vol. 129; no. 6; pp. 749 - 757
Main Authors Kazuhiro OZAWAa, Hironobu MINAMIb, c, Hitoshi SATOa
Format Journal Article
LanguageJapanese
Published Pharmaceutical Society of Japan 01.06.2009
Online AccessGet full text
ISSN0031-6903
DOI10.1248/yakushi.129.749

Cover

Abstract This study was aimed to perform clinical trial simulations to evaluate the dose reduction strategy of docetaxel for Japanese patients with liver dysfunction, which we previously proposed. For this purpose, a log-binominal regression (LBR) was performed for febrile neutropenia (FN) induced by docetaxel in these patients. A LBR analysis was conducted using clinical data from cancer patients treated with docetaxel and incorporated in the subsequent trial simulation. Virtual patients with liver dysfunction were randomly assigned to receive the Japanese standard dose (60 mg/m2) or reduced dose (40 or 50 mg/m2) of docetaxel. The primary endpoint was overall survival of the reduced dose to the standard dose. The secondary endpoint was the number of patients who experienced FN in response to the two treatment regimens. From the LBR analysis, the performance status and the area under the plasma concentration-time curve (AUC) were selected as covariates associated significantly (p<0.05) with FN occurrence. From the results of the present trial simulation, the median proportion of patients who experienced FN was decreased by about 20% in the reduced dose arm. Non-inferiority criteria, the reduced dose group to the standard dose group were met in 85.5% of the simulated clinical trials with a decrease in the FN frequency. In conclusion, clinical trial simulation models for the efficacy (survival) and toxicity (FN) was first performed in Japanese patients, and the feasibility of docetaxel therapy for liver-dysfunction patients under the dose reduction strategy was supported.
AbstractList This study was aimed to perform clinical trial simulations to evaluate the dose reduction strategy of docetaxel for Japanese patients with liver dysfunction, which we previously proposed. For this purpose, a log-binominal regression (LBR) was performed for febrile neutropenia (FN) induced by docetaxel in these patients. A LBR analysis was conducted using clinical data from cancer patients treated with docetaxel and incorporated in the subsequent trial simulation. Virtual patients with liver dysfunction were randomly assigned to receive the Japanese standard dose (60 mg/m2) or reduced dose (40 or 50 mg/m2) of docetaxel. The primary endpoint was overall survival of the reduced dose to the standard dose. The secondary endpoint was the number of patients who experienced FN in response to the two treatment regimens. From the LBR analysis, the performance status and the area under the plasma concentration-time curve (AUC) were selected as covariates associated significantly (p<0.05) with FN occurrence. From the results of the present trial simulation, the median proportion of patients who experienced FN was decreased by about 20% in the reduced dose arm. Non-inferiority criteria, the reduced dose group to the standard dose group were met in 85.5% of the simulated clinical trials with a decrease in the FN frequency. In conclusion, clinical trial simulation models for the efficacy (survival) and toxicity (FN) was first performed in Japanese patients, and the feasibility of docetaxel therapy for liver-dysfunction patients under the dose reduction strategy was supported.
Author Hitoshi SATOa
Kazuhiro OZAWAa
c
Hironobu MINAMIb
Author_xml – sequence: 1
  fullname: Kazuhiro OZAWAa
– sequence: 2
  fullname: Hironobu MINAMIb
– sequence: 3
  fullname: c
– sequence: 4
  fullname: Hitoshi SATOa
BookMark eNotkM1OwzAMx3MYEgN25poHoCNd2qQ9wmCANDEE41wlqbNldMnUtMB4GV4VD_DBlj_-tvU7IQMfPBBynrJxOsmKy7166-PaYVKOZVYOyJAxniaiZPyYjGJ0mrEJWp4WQ_I9bZx3RjV02Tr0L27bN6pzwUdqQ0tvQlQroItd57bu67dBg8WygU59QkOdp09YBt9F-uG6NZ27d0DdPtrem8P8Bb1WEWqKSkXnYZVo58PWebz2DKsW8CNsHY7NQLeuAfoIfdeGHXinzsiRVU2E0X88Ja-z2-X0Ppkv7h6mV_Nkw7O8S-raWA7aSMUFQqhTECznYISUsshkUWRWc6PtJEvLGqwVNteCS13XQssyN_yUzP72bqE-4AgeuUC1CX2Lj8bKRHnguqomjJUVQ7ZMYOAVQ8TocimyghUZ_wFi8Hte
ContentType Journal Article
CorporateAuthor National Cancer Center Hospital East
bThe Division of Oncology/Hematology
aDepartment of Clinical and Molecular Pharmacokinetics/Pharmacodynamics
Kobe University Hospital and Graduate School of Medicine
School of Pharmaceutical Sciences
Department of Medicine
Showa University
cMedical Oncology
CorporateAuthor_xml – name: School of Pharmaceutical Sciences
– name: Showa University
– name: bThe Division of Oncology/Hematology
– name: Department of Medicine
– name: Kobe University Hospital and Graduate School of Medicine
– name: cMedical Oncology
– name: aDepartment of Clinical and Molecular Pharmacokinetics/Pharmacodynamics
– name: National Cancer Center Hospital East
DOI 10.1248/yakushi.129.749
DatabaseTitleList
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EndPage 757
ExternalDocumentID cs7yakug_2009_012906_013_0749_0757648084
GroupedDBID .55
123
29R
2WC
53G
ADBBV
AFFNX
ALMA_UNASSIGNED_HOLDINGS
BAWUL
CS3
DIK
E3Z
EBS
EJD
F5P
GX1
HH5
JMI
JSF
JSH
KQ8
LPU
MOJWN
OVT
P2P
RJT
RNS
RZJ
X7J
X7M
XSB
ID FETCH-LOGICAL-j345t-ddcf3ebc7a36124d1e6053ec6777847884fb3cbf2419deff6f5b637bdd6b795c3
ISSN 0031-6903
IngestDate Thu Jul 10 16:12:08 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 6
Language Japanese
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-j345t-ddcf3ebc7a36124d1e6053ec6777847884fb3cbf2419deff6f5b637bdd6b795c3
PageCount 9
ParticipantIDs medicalonline_journals_cs7yakug_2009_012906_013_0749_0757648084
PublicationCentury 2000
PublicationDate 2009-06-01
PublicationDateYYYYMMDD 2009-06-01
PublicationDate_xml – month: 06
  year: 2009
  text: 2009-06-01
  day: 01
PublicationDecade 2000
PublicationTitle YAKUGAKU ZASSHI (Journal of the Pharmaceutical Society of Japan)
PublicationYear 2009
Publisher Pharmaceutical Society of Japan
Publisher_xml – name: Pharmaceutical Society of Japan
SSID ssib002222518
ssib002223935
ssib000959844
ssib002822080
ssib003105265
ssib023161479
ssj0023355
ssib000576198
ssib002499502
ssib003105266
ssib000937675
ssib000972830
ssib001536036
ssib002222551
ssib058494605
ssib058494604
Score 1.9446788
Snippet This study was aimed to perform clinical trial simulations to evaluate the dose reduction strategy of docetaxel for Japanese patients with liver dysfunction,...
SourceID medicalonline
SourceType Publisher
StartPage 749
Title Clinical Trial Simulations for Dosage Optimization of Docetaxel in Patients with Liver Dysfunction, Based on a Log-binominal Regression for Febrile Neutropenia
URI http://mol.medicalonline.jp/en/journal/download?GoodsID=cs7yakug/2009/012906/013&name=0749-0757e
Volume 129
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVFSB
  databaseName: Free Full-Text Journals in Chemistry
  issn: 0031-6903
  databaseCode: HH5
  dateStart: 18810101
  customDbUrl:
  isFulltext: true
  dateEnd: 99991231
  titleUrlDefault: http://abc-chemistry.org/
  omitProxy: true
  ssIdentifier: ssj0023355
  providerName: ABC ChemistRy
– providerCode: PRVBFR
  databaseName: Free Medical Journals
  issn: 0031-6903
  databaseCode: DIK
  dateStart: 19470101
  customDbUrl:
  isFulltext: true
  dateEnd: 99991231
  titleUrlDefault: http://www.freemedicaljournals.com
  omitProxy: true
  ssIdentifier: ssj0023355
  providerName: Flying Publisher
– providerCode: PRVFQY
  databaseName: GFMER Free Medical Journals
  issn: 0031-6903
  databaseCode: GX1
  dateStart: 0
  customDbUrl:
  isFulltext: true
  dateEnd: 99991231
  titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php
  omitProxy: true
  ssIdentifier: ssj0023355
  providerName: Geneva Foundation for Medical Education and Research
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Jb9NAFB6FcgEhxCp2zQH14rgkGdtjn5DVUJKGNBVJROklmvHSuCixVNsS6Z_hb3LkPS_xuEWiwCFOxvEmz3zvfW_mLYS8BTPWBi3t6RJ0j26YgukiYFxH9iCY37VCH4OTx0fWYG4cnpgnrdZPxWspS-Wed_nbuJJ_6VXYB_2KUbJ_0bPbi8IO-A39C1voYdjeqI_3q7DGWV57Yxqtssq1Db0H-zF6jWkTkAqrMtwSuSHolSAV3wPMtoEp-qM6yO0Temlo_U2C6i53-8iXJBJgpei1jAV-0ZSOi0pgn4Ozwou2cFY8APMaZAzIzSzFKf51JFTq-9UdzT_CRzt1p9PBEKmtwoaR_x4vG_PrlUMp_HsIKn2tTFqMxGW2jC5ibXLqfnG3mmWAMXuxzLTx8MgdD2W136sPSONkGWlTdzYRjQkPp3bMyofoH55FFfasq4PxzxrCvnzU6Jro5kXq1JIF8CJt9jUF0zMwaGIjvmXwtNB09rbnNbJ2ewnHg86wzKezyGf7LPhiC6Bs0IbLW4bdsY1b5HYP9BEWHekPRwqRxuklhSg7V7LuOKZjq3ULHI6Z3BQizKwOUxPhgdxWWEjeVtaDkSU6KnEGQ9jsNNbbex1F0oNR0KirULS39wOjAWhfvf4LLNcxlCxAZbvOismYWdQaKbusTMIFb_vdlXd9l9xbFUuYRSoZhQ3OHpD75cClboHJh6R1Lh6R3XLQbNp0Voc1Jm26S4_rDPGbx-RHBVyaA5cqwKWAJFoAl6rApXFIt8Cl0ZpWwKUIXJoDlyrAbdMcthTOFLQBW1rDNr9ZCVuqwPYJmR98mO0P9LJSin7ODDPVfd8LWSA9LhhYLIbfDeDlssCzOAdRzG3bCCXzZAh03fGDMLRCU1qMS9-3JHdMjz0lO-t4HTwjlHX8Xg9Gk8-FbQSW6YQe95jsdi1hBkAGnpP3jfe_KOVhsrjpkH_x31d4Se7UguEV2UkvsuA12AapfJPD6Behc_xQ
linkProvider Flying Publisher
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Clinical+Trial+Simulations+for+Dosage+Optimization+of+Docetaxel+in+Patients+with+Liver+Dysfunction%2C+Based+on+a+Log-binominal+Regression+for+Febrile+Neutropenia&rft.jtitle=YAKUGAKU+ZASSHI+%28Journal+of+the+Pharmaceutical+Society+of+Japan%29&rft.au=Kazuhiro+OZAWAa&rft.au=Hironobu+MINAMIb&rft.au=c&rft.au=Hitoshi+SATOa&rft.date=2009-06-01&rft.pub=Pharmaceutical+Society+of+Japan&rft.issn=0031-6903&rft.volume=129&rft.issue=6&rft.spage=749&rft.epage=757&rft_id=info:doi/10.1248%2Fyakushi.129.749&rft.externalDocID=cs7yakug_2009_012906_013_0749_0757648084
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0031-6903&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0031-6903&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0031-6903&client=summon